Proton pump inhibitor-related headaches: A nationwide population-based case-crossover study in Taiwan

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Cephalalgia

• Publication date

  2015-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/0333102414535114PMID 24853165
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prevalence of neck pain in migraine and tension-type headache: A population study

  2015cited by this paper
• Does Health Information Exchange Reduce Unnecessary Neuroimaging and Improve Quality of Headache Care in the Emergency Department?

  2013cited by this paper
• Lansoprazole

  2012cited by this paper
• A meta-analytic approach to estimating nocebo effects in neuropathic pain trials

  2012cited by this paper
• Esomeprazole

  2012cited by this paper
• Esomeprazole

  2012cited by this paper
• Recent safety concerns with proton pump inhibitors.

  2012cited by this paper
• Comorbidity profiles of chronic migraine sufferers in a national database in Taiwan

  2012cited by this paper
• Systematic review: hypomagnesaemia induced by proton pump inhibition

  2012cited by this paper
• Validation of the national health insurance research database with ischemic stroke cases in Taiwan

  2011cited by this paper
• Influence of retirement and work stress on headache prevalence: A longitudinal modelling study from the GAZEL Cohort Study

  2011cited by this paper
• Update on the pharmacogenomics of proton pump inhibitors.

  2011cited by this paper
• The Emergency Department

  2010cited by this paper
• Histamine2-receptor antagonists are an alternative to proton pump inhibitor in patients receiving clopidogrel.

  2010cited by this paper
• Epidemiology of headache.

  2010cited by this paper
• Adverse effects of proton pump inhibitor drugs: clues and conclusions

  2010cited by this paper
• Gender and the nocebo response following conditioning and expectancy.

  2009cited by this paper
• Rabeprazole

  2009cited by this paper
• Utilization, Diagnosis, Treatment and Cost of Migraine Treatment in the Emergency Department

  2009cited by this paper
• Economic Reflections on Proton Pump Inhibitor Therapy for Non-Erosive Reflux Disease

  2008influential reference
• Proton pump inhibitors: an update of their clinical use and pharmacokinetics

  2008cited by this paper
• Safety Profile of Esomeprazole

  2008cited by this paper
• Epidemiology and comorbidity of headache.

  2008cited by this paper
• GERD prevalence in migraine patients and the implication for acute migraine treatment

  2008cited by this paper
• Dopamine and Migraine: Biology and Clinical Implications

  2007cited by this paper
• Safety profile of proton pump inhibitors according to the spontaneous reports of suspected adverse reactions.

  2006cited by this paper
• Accuracy of diabetes diagnosis in health insurance claims data in Taiwan.

  2005cited by this paper
• Drug-induced headache.

  2004cited by this paper
• Treatment of primary headache in the emergency department.

  2004cited by this paper
• The Pharmacovigilance of Pantoprazole

  2003cited by this paper
• Treatment of Primary Headache in the Emergency Department

  2003cited by this paper
• Determinants of Headache in Lansoprazole Users in The Netherlands

  2002influential reference
• Epidemiology of Headache

  2001cited by this paper
• The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies.

  2000influential reference
• Rabeprazole: a review of its use in acid-related gastrointestinal disorders.

  1999cited by this paper
• No increase in demyelinating diseases after hepatitis B vaccination

  1999cited by this paper
• Investigating the Relationship Between β‐Blocker and Antidepressant Use Through Linkage of the Administrative Databases of Saskatchewan Health

  1997cited by this paper
• Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders.

  1997cited by this paper
• Headache Induced by a Nitric Oxide Donor (nitroglycerin) Responds to Sumatriptan. A Human Model for Development of Migraine Drugs

  1996cited by this paper
• Pantoprazole Review of its Pharmacological Properties and Therapeutic Use in Acid-Related Disorders

  1996cited by this paper
• The case-crossover design: a method for studying transient effects on the risk of acute events.

  1991cited by this paper
• Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders.

  1991cited by this paper
• The Association of Frequent Headaches with Personality and Life Events

  1991cited by this paper
• [Drug-induced headache].

  1986cited by this paper

• Effects of proton pump inhibitor (PPI) use on migraine – a critical review

  2025cites this paper
• Dose-dependent association between proton pump inhibitor use and the risk of migraine: a nationwide matched case-control study.

  2025cites this paper
• Association between proton pump inhibitor use and migraine: a systematic review and meta-analysis

  2025influential citation
• Association between CYP2C19 polymorphism and proton pump inhibitors adverse drug reactions: a narrative review

  2025cites this paper
• Use of Acid-Suppression Therapy and Odds of Migraine and Severe Headache in the National Health and Nutrition Examination Survey.

  2024cites this paper
• New Daily Persistent Headaches with Migrainous Features Following Proton Pump Inhibitor Use: A Case Report and Literature Review

  2024cites this paper
• International Headache Society global practice recommendations for the acute pharmacological treatment of migraine

  2024cites this paper
• Proton Pump Inhibitors and Cognitive Health: Review on Unraveling the Dementia Connection and Co-morbid Risks

  2024cites this paper
• Mechanistic Insight into the Inhibition of Choline Acetyltransferase by Proton Pump Inhibitors.

  2023cites this paper
• Evaluating the use of methods to mitigate bias from non‐transient medications in the case‐crossover design: A systematic review

  2023cites this paper
• Relevance of early management by proton-pump inhibitor in acute upper gastro-intestinal tract disorder: A scoping review.

  2023cites this paper
• Association between Migraines and Prior Proton Pump Inhibitor Use: A Nested Case-Control Study Using a National Health Screening Cohort

  2022influential citation
• Regular proton pump inhibitor use and incident dementia: population-based cohort study

  2022cites this paper
• Association between migraine prevalence, treatment with proton-pump inhibitors and CYP2C19 phenotypes in UK Biobank.

  2021influential citation
• The Janus-like Association between Proton Pump Inhibitors and Dementia

  2021cites this paper
• Unexpected beneficial effects of drugs: an analysis of cases in the Dutch spontaneous reporting system

  2021cites this paper
• Proton-pump inhibitor use is associated with a broad spectrum of neurological adverse events including impaired hearing, vision, and memory

  2019cites this paper
• A Review on Complications of the Prolonged Use of Proton Pump Inhibitors (PPIs) and Presenting a Case of Barrett’s Esophagus

  2018cites this paper
• Proton Pump Inhibitors and Dementia: Physiopathological Mechanisms and Clinical Consequences

  2018cites this paper
• An update on type 2 diabetes management in primary care

  2017cites this paper
• Overuse of proton pump inhibitors and its consequences.

  2016cites this paper
• Chapter 34 – Gastrointestinal Drugs

  2016cites this paper
• Is the way to headache through the stomach?

  2015cites this paper
• Event-Specific Risk Factors Predicting Episodes of Unprotected Anal Intercourse with Male Nonregular Partners among Men Who Have Sex with Men Using Case-Crossover Study Design

  2014cites this paper